Aura Biosciences, Inc.
AURA
$7.67
$0.020.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 52.84% | 1.98% | -1.41% | 3.58% | 11.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.04% | 15.35% | 17.35% | 21.78% | 20.30% |
| Operating Income | -27.04% | -15.35% | -17.35% | -21.78% | -20.30% |
| Income Before Tax | -29.32% | -18.69% | -22.21% | -28.15% | -25.77% |
| Income Tax Expenses | -39.10% | 17.65% | -5.31% | -48.67% | -27.32% |
| Earnings from Continuing Operations | -29.23% | -18.69% | -22.17% | -27.94% | -25.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.23% | -18.69% | -22.17% | -27.94% | -25.65% |
| EBIT | -27.04% | -15.35% | -17.35% | -21.78% | -20.30% |
| EBITDA | -27.43% | -15.63% | -17.67% | -22.19% | -20.71% |
| EPS Basic | 10.09% | 8.29% | -2.36% | -11.54% | -9.26% |
| Normalized Basic EPS | 10.04% | 8.29% | -2.38% | -11.42% | -9.07% |
| EPS Diluted | 10.09% | 8.29% | -2.36% | -11.54% | -9.26% |
| Normalized Diluted EPS | 10.04% | 8.29% | -2.38% | -11.42% | -9.07% |
| Average Basic Shares Outstanding | 42.17% | 29.72% | 21.44% | 15.88% | 14.25% |
| Average Diluted Shares Outstanding | 42.17% | 29.72% | 21.44% | 15.88% | 14.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |